SCHEDULE 13G/A: BlackRock Discloses 7.1% Stake in Amylyx Pharmaceuticals
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.1% beneficial ownership stake in Amylyx Pharmaceuticals, Inc. as of December 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 7,783,648 shares of Amylyx Pharmaceuticals, Inc. Common Stock.
- This ownership represents 7.1% of the total outstanding shares of the class.
- BlackRock holds sole voting power over 7,653,538 shares and sole dispositive power over 7,783,648 shares.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Amylyx Pharmaceuticals, Inc.
- The filing was made under Rule 13d-1(b), indicating BlackRock's status as an institutional investor.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership by a large institutional investor, BlackRock, Inc., in Amylyx Pharmaceuticals, Inc. It does not contain specific positive or negative news about the issuer's operations or financial performance, thus maintaining a neutral sentiment.
Positives
- BlackRock, a prominent institutional investor, maintaining a significant 7.1% stake in Amylyx Pharmaceuticals, Inc. can be interpreted as a vote of confidence in the company's long-term prospects.
Future Outlook
NA
Industry Context
This filing indicates continued institutional interest in the pharmaceutical sector, with a major asset manager like BlackRock maintaining a significant position in Amylyx Pharmaceuticals. Such substantial holdings are common for companies in the healthcare and biotechnology sectors, reflecting their potential for long-term growth or stability, particularly for firms with approved or pipeline products.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by BlackRock may provide a degree of confidence or stability, indicating a major investor's continued interest in the company.
- Management: Awareness of a large institutional holder like BlackRock can influence management's strategic decisions and communication with the investment community.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of the event which required the filing of this statement, reflecting the reported ownership position. |
| 01/21/2026 | Date of filing and execution of the Schedule 13G Amendment No. 1 by BlackRock, Inc. |
Keywords
Amylyx Pharmaceuticals, BlackRock, Institutional Ownership, Common Stock, Schedule 13G, Beneficial Ownership, AMLYX, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.